Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|September 7, 2007
Carl Zeiss Meditec cancels takeover of WaveLight
Jena, Germany-A decision has been made by Carl Zeiss Meditec AG not to make the voluntary takeover bid for WaveLight Laser Technologies AG.
Advertisement
Jena, Germany-A decision has been made by Carl Zeiss Meditec AG not to make the voluntary takeover bid for WaveLight Laser Technologies AG.
"After carefully considering a possible takeover of WaveLight and assessing the resulting synergies which could be expected, we have decided not to pursue this option any further," said Bernd Hirsch, CFO of Carl Zeiss Meditec AG.
"Therefore, we will tender our share package at the terms of the existing voluntary, public tender offer," continued Hirsch.
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Comments from the FDA Advisory Committee meeting on SYD-101
2
Q&A: Phentolamine for presbyopia: a non-miotic route to near vision
3
Lambert-Eaton Myasthenic Syndrome: how eye care professionals differentiate it from myasthenia gravis
4
Practical ways to extend anti-VEGF control in RVO, AMD, and DME
5